1 |
Wells KE, Peterson EL, Ahmedani BK, Severson RK, Gleason- Comstock J, Williams LK. The relationship between combination inhaled corticosteroid and long-acting beta-agonist use and severe asthma exacerbations in a diverse population. J Allergy Clin Immunol 2012;129:1274-9.e2.
DOI
ScienceOn
|
2 |
Sumino K, Sugar EA, Irvin CG, Kaminsky DA, Shade D, Wei CY, et al. Methacholine challenge test: diagnostic characteristics in asthmatic patients receiving controller medications. J Allergy Clin Immunol 2012;130:69-75.e6.
DOI
ScienceOn
|
3 |
Jia G, Erickson RW, Choy DF, Mosesova S, Wu LC, Solberg OD, et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol 2012;130:647-54.e10.
DOI
|
4 |
Greenberg S, Liu N, Kaur A, Lakshminarayanan M, Zhou Y, Nelsen L, et al. The asthma disease activity score: a discriminating, responsive measure predicts future asthma attacks. J Allergy Clin Immunol 2012;130:1071-7.e10.
DOI
ScienceOn
|
5 |
Eisner MD, Yegin A, Trzaskoma B. Severity of asthma score predicts clinical outcomes in patients with moderate to severe persistent asthma. Chest 2012;141:58-65.
DOI
ScienceOn
|
6 |
Schatz M, Zeiger RS, Yang SJ, Chen W, Crawford W, Sajjan S, et al. The relationship of asthma impairment determined by psychometric tools to future asthma exacerbations. Chest 2012;141:66-72.
DOI
ScienceOn
|
7 |
Hawkins GA, Robinson MB, Hastie AT, Li X, Li H, Moore WC, et al. The IL6R variation Asp(358)Ala is a potential modifier of lung function in subjects with asthma. J Allergy Clin Immunol 2012;130:510-5.e1.
DOI
ScienceOn
|
8 |
Wan YI, Shrine NR, Soler Artigas M, Wain LV, Blakey JD, Moffatt MF, et al. Genome-wide association study to identify genetic determinants of severe asthma. Thorax 2012;67:762-8.
DOI
ScienceOn
|
9 |
Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360:973-84.
DOI
ScienceOn
|
10 |
Brusselle GG, Vanderstichele C, Jordens P, Deman R, Slabbynck H, Ringoet V, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax 2013;68:322-9.
DOI
ScienceOn
|
11 |
Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA Jr, Criner GJ, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011;365:689-98.
DOI
ScienceOn
|
12 |
Sutherland ER, King TS, Icitovic N, Ameredes BT, Bleecker E, Boushey HA, et al. A trial of clarithromycin for the treatment of suboptimally controlled asthma. J Allergy Clin Immunol 2010;126:747-53.
DOI
ScienceOn
|
13 |
Kerstjens HA, Engel M, Dahl R, Paggiaro P, Beck E, Vandewalker M, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med 2012;367:1198-207.
DOI
ScienceOn
|
14 |
Calhoun WJ, Ameredes BT, King TS, Icitovic N, Bleecker ER, Castro M, et al. Comparison of physician-, biomarker-, and symptom-based strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: the BASALT randomized controlled trial. JAMA 2012;308:987-97.
DOI
ScienceOn
|
15 |
Brozek JL, Kraft M, Krishnan JA, Cloutier MM, Lazarus SC, Li JT, et al. Long-acting beta2-agonist step-off in patients with controlled asthma. Arch Intern Med 2012;172:1365-75.
DOI
ScienceOn
|
16 |
Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012;380:651-9.
DOI
ScienceOn
|